

# Monika Kasprzycka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10842096/publications.pdf>

Version: 2024-02-01

21  
papers

908  
citations

567281

15  
h-index

940533

16  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1574  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuclear IL-33 restrains the early conversion of fibroblasts to an extracellular matrix-secreting phenotype. <i>Scientific Reports</i> , 2021, 11, 108.	3.3	17
2	Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients. <i>PLoS ONE</i> , 2020, 15, e0243759.	2.5	1
3	Title is missing!. , 2020, 15, e0243759.		0
4	Title is missing!. , 2020, 15, e0243759.		0
5	Title is missing!. , 2020, 15, e0243759.		0
6	Title is missing!. , 2020, 15, e0243759.		0
7	Inhibition of Endothelial NOTCH1 Signaling Attenuates Inflammation by Reducing Cytokine-Mediated Histone Acetylation at Inflammatory Enhancers. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 854-869.	2.4	37
8	Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. <i>Transplant International</i> , 2017, 30, 827-840.	1.6	16
9	Interleukin-33 Drives a Proinflammatory Endothelial Activation That Selectively Targets Nonquiescent Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, e47-55.	2.4	44
10	The Alarmin IL-33 Is a Notch Target in Quiescent Endothelial Cells. <i>American Journal of Pathology</i> , 2012, 181, 1099-1111.	3.8	61
11	Inflammatory Bowel Disease-Associated Interleukin-33 Is Preferentially Expressed in Ulceration-Associated Myofibroblasts. <i>American Journal of Pathology</i> , 2010, 177, 2804-2815.	3.8	151
12	Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches. <i>Seminars in Oncology</i> , 2009, 36, S27-S35.	2.2	39
13	Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas. <i>American Journal of Pathology</i> , 2009, 175, 817-824.	3.8	18
14	IL-21 Enhances Antitumor Responses without Stimulating Proliferation of Malignant T Cells of Patients with SÅ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2008, 128, 473-480.	0.7	17
15	Differential Effects of Interleukin-2 and Interleukin-15 versus Interleukin-21 on CD4+ Cutaneous T-Cell Lymphoma Cells. <i>Cancer Research</i> , 2008, 68, 1083-1091.	0.9	79
16	Î³c-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes. <i>Journal of Immunology</i> , 2008, 181, 2506-2512.	0.8	56
17	IL-2â€ and IL-15â€ induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. <i>Blood</i> , 2008, 111, 2181-2189.	1.4	62
18	Expression and Oncogenic Role of Brk (PTK6/Sik) Protein Tyrosine Kinase in Lymphocytes. <i>American Journal of Pathology</i> , 2006, 168, 1631-1641.	3.8	37

#	ARTICLE	IF	CITATIONS
19	Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9964-9969.	7.1	135
20	Activation of Mammalian Target of Rapamycin in Transformed B Lymphocytes Is Nutrient Dependent but Independent of Akt, Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase, Insulin Growth Factor-I, and Serum. Cancer Research, 2005, 65, 7800-7808.	0.9	74
21	Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Laboratory Investigation, 2005, 85, 1544-1554.	3.7	64